BioReact is a technology company.
BioReact has raised $120K across 1 funding round.
BioReact has raised $120K in total across 1 funding round.
BioReact has raised $120K in total across 1 funding round.
BioReact's investors include Techstars, TSVC Capital, XX, Anthony Pompliano, Furqan Rydhan, Trevor Blackwell.
BioReact is a biotech software company headquartered in Indianapolis, Indiana, that builds an AI-powered platform for bioprocess optimization in fermentation and bioreactor workflows[1][2][3][4]. The platform unifies data from instruments, automates analysis with tools like Design of Experiments (DOE), PCA, ANOVA, and proprietary Opti-ML AI models to recommend optimal conditions such as temperature, pH, feed rates, and media composition—solving data fragmentation that slows development cycles[1][2][3]. It serves bioprocess scientists, engineers, CDMOs, and R&D teams in biopharma, synthetic biology, cultured meat, and industrial fermentation, shortening iterations by up to 20% and accelerating planet-positive innovations like sustainable fuels, materials, and foods[1][2][3].
Early growth includes securing 54 pilot users and a Synonym Bio partnership within months of launch, without paid ads, alongside a public platform release in July 2025 demonstrating strong momentum[1][2].
BioReact emerged from founders witnessing disconnected data throttling fermentation breakthroughs in labs worldwide[1]. Mitchell J. Castetter, CEO with sales and bioprocess expertise, translated scientist needs into product requirements; Joanna, deep tech leader, architected the cloud-native platform for terabytes of time-series and omics data; engineers and data scientists with bioprocess optimization experience built the Opti-ML algorithm[1]. The idea crystallized into a unified fermentation data platform connecting instruments, automating analysis, and delivering AI/ML insights[1].
Pivotal early validation came quickly: within months, BioReact gained 54 pilot users and partnered with Synonym Bio, using feedback to refine features like automated time-series alignment and AI parameter optimization—fueling organic traction as a member of the Indiana Life Sciences Association since 2025[1][4].
BioReact rides the AI-biotech convergence trend, addressing data silos in bioprocess development amid rising demand for sustainable bio-economy solutions like eco-fuels, materials, and cultured proteins[1][2]. Timing aligns with synthetic biology's growth, where fragmented tools slow cycles; BioReact's cloud-native unification and predictive modeling cut costs and time, favoring market forces like precision fermentation scaling[1][3]. It influences the ecosystem by empowering in-house R&D and CDMOs, accelerating "bench-to-market" for planet-positive innovations and integrating with major bioreactors to standardize workflows[1][2][3][4].
BioReact is poised to expand as AI matures in bioprocessing, potentially dominating with deeper integrations, more omics support, and enterprise-scale deployments amid synthetic bio's projected boom[1][2][3]. Trends like real-time analytics and custom ML uploads will shape it, evolving its influence from pilot darling to essential infrastructure—unifying data to propel more sustainable breakthroughs from lab to market[1].
BioReact has raised $120K across 1 funding round. Most recently, it raised $120K Seed in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $120K Seed | Techstars, TSVC Capital, XX, Anthony Pompliano, Furqan Rydhan, Trevor Blackwell |